Dr. Adam Schoenfeld, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
13 reported clinical trials
25 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage III
SMARCA4 positive
2Non-Small Cell Lung Cancer
Stage IV
KRAS positive
ALK positive
Affiliated Hospitals
Clinical Trials Adam Schoenfeld, MD is currently running
CAR T-Cell Therapy
for Small Cell Lung Cancer
This trial tests specially modified immune cells in patients with advanced lung cancers. These immune cells are designed to find and destroy cancer cells by targeting a specific protein on them.
Recruiting1 award Phase 112 criteria
STK-012 + Pembrolizumab
for Cancer
This trial is testing a new drug called STK-012 alone and with another medication in patients with advanced solid tumors that haven't responded to usual treatments. The aim is to find the right dose and see how well it works.
Recruiting1 award Phase 13 criteria
More about Adam Schoenfeld, MD
Clinical Trial Related6 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Adam Schoenfeld, MD has experience with
- Pembrolizumab
- Fludarabine
- Cyclophosphamide
- GSK3901961
- GSK4427296
- GSK3845097
Breakdown of trials Adam Schoenfeld, MD has run
Lung Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- CAR T-Cell Therapy for Small Cell Lung Cancer
- ITIL-306 for Advanced Cancer
Non-Small Cell Lung Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- STK-012 + Pembrolizumab for Cancer
- ITIL-306 for Advanced Cancer
Solid Tumors
Tumors
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- Engineered T Cell Therapy for Cancer
- LY4050784 for Advanced Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Adam Schoenfeld, MD specialize in?
Adam Schoenfeld, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Adam Schoenfeld, MD currently recruiting for clinical trials?
Yes, Adam Schoenfeld, MD is currently recruiting for 5 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Adam Schoenfeld, MD has studied deeply?
Yes, Adam Schoenfeld, MD has studied treatments such as Pembrolizumab, Fludarabine, Cyclophosphamide.
What is the best way to schedule an appointment with Adam Schoenfeld, MD?
Apply for one of the trials that Adam Schoenfeld, MD is conducting.
What is the office address of Adam Schoenfeld, MD?
The office of Adam Schoenfeld, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.